Norbert Riedel - Jun 5, 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Jun 5, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/7/2024, 04:30 PM
Previous filing: Feb 15, 2024
Next filing: Aug 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Award		+10.5K	+22.7%		56.6K	Jun 5, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.

Content

The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.